Skip to main content

Table 2 Summary of main findings

From: Targeting CK2 mediated signaling to impair/tackle SARS-CoV-2 infection: a computational biology approach

Analysis type Subject Identity Working hypothesis Experimental clues References
Individual CK2 sites Viral proteins N CK2 phosphosite inhibition/blockage by CIGB-300 impairs viral replication Interaction, co-localization, N mRNA and protein expression inhibition by CIGB-300 in a subrogate model Ramon et al. (2021)
Individual CK2 sites Viral proteins Orf6 CK2 phosphosite inhibition/blockage by CIGB-300 restores IFN signaling Additive/Synergistic profile of CIGB-300 plus IFN alpha Unpublished
Co-Expression and network propagation Host and Viral Proteins B23, Orf6, NUP98 CK2 phosphosite inhibition/blockage by CIGB-300 restores IFN signaling Additive/Synergistic profile of CIGB-300 plus IFN alpha Unpublished
Phosphoproteome overlap Host Proteins MATR3, SQSTM1, DIDO1 CIGB-300 Multitarget effect impairing viral transcription/splicing, inflammation, immunoresponse and apoptosis Pulmonary lesions resolution in CT Phase I Cruz et al. (2020)
Enrichment analysis at early viral infection and Kinase activity profiles Host proteins SRPK1 (SRSF1 and SRSF-2,6,10) CIGB-300 impairs SRSF1 role in viral protein synthesis None, to be evaluated in preclinical settings NA
PPIs vs H125 Phosphoproteome Host and Viral Proteins Several proteins (see text and Fig. 7) [LARP1, LARP7, LARP4B] CIGB-300 impairs Viral RNA processing and transcription None, to be evaluated in preclinical settings NA
SARS-CoV-2 vs H125 Phosphoproteome overlap, Network and Enrichment analysis Host proteins Several proteins (see text and Fig. 8)
[HNRNPA1, HSPB1, SRRM2, SRRM1, B23]
CIGB-300 Multitarget effect impairing on mRNA metabolism, cell cycle and Autophagy pathways Pulmonary lesions resolution in CT Phase I Cruz et al. (2020)
Enrichment of Human Phenotypes Host proteins HNPRNPA1, MATR3, SQSTM1, B23, FIP1L1, NUMA1 CIGB-300 may relief Covid-19 clinical symptoms To be evaluated in CT Phase II NA